The summary of the Study is to compare two methods in order to predict how the 1-HIV will use a co-receptor: the use of an accredited test (TROFILE ESTA®) and the viral response to a CCR5 antagonist in the short term.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
58
The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain
Hospital Ramón y Cajal
Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
To determine if there is a correlation between the Trofile ESTA® test for viral tropism and the viral load reduction after a short treatment with maraviroc in naïve patients (patients with no previous HAART)
Time frame: 10 days of treatment per patient
To establish a viral load reduction cut point, which would differentiate R5-tropic virus from non-R5 tropic virus(X4/dual/mixed).
Time frame: 1 month per patient
To assess the viral response to a CCR5 antagonist according to the viral tropism identified in the phenotypic Study.
Time frame: 1 month per patient
Safety assessment throughout the Study
Time frame: 12 months
Maraviroc effects assessment in the drug-resistance evolution in naïve patients
Time frame: 12 months
Tropism changes assessment since the Screening period
Time frame: 1 month per patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.